| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b08331191edf52b8907dd1b18d355982 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5585
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0053
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-557
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0073
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5575
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-343
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-191
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-513
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-522
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5578
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-34 |
| filingDate |
2013-05-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2015-03-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b4d40dd8f3a5e1b552c2557580b24917
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f97b80078b67d5f57bd570eae43222fa |
| publicationDate |
2015-03-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-8969409-B2 |
| titleOfInvention |
Treatment for pulmonary hypertension |
| abstract |
One embodiment relates to a method of treating pulmonary hypertension based upon co-administering to a subject in need thereof a pharmaceutically effective amount of an oral therapeutic agent for treating pulmonary hypertension and a pharmaceutically effective amount of an inhaled therapeutic agent for treating pulmonary hypertension. The benefit of the co-administration of these agents is to eliminate or reduce one or more side effects associated with mono-therapy of either agent, as well as one or more side effects associated with other administration routes such as subcutaneous or intravenous administration. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9469600-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10010518-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10343979-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11759425-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2023154705-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11148997-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10526274-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11458098-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10995055-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2015192030-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2020232046-A1 |
| priorityDate |
2010-03-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |